Table 3.
Adverse events in the different treatment groups
|
Adverse effect
|
All
|
500 mg bid (n = 73)
|
500 mg tid (n = 74)
|
750 mg bid (n = 71)
|
P value
|
| Total, n/N (%)1 | 22.5 (49/218) | 12.3 (9/73) | 31.1 (23/74) | 23.9 (17/71) | 0.023 |
| Taste distortion | 1 | 0 | 1 | 0 | |
| Belching | 1 | 0 | 1 | 0 | |
| Loss of appetite | 3 | 0 | 1 | 2 | |
| Nausea | 5 | 1 | 3 | 1 | |
| Vomiting | 4 | 1 | 1 | 2 | |
| Abdominal pain | 1 | 0 | 1 | 0 | |
| Bloating | 3 | 0 | 3 | 0 | |
| Diarrhea | 3 | 1 | 0 | 2 | |
| Skin rash | 4 | 2 | 1 | 1 | |
| Fever | 3 | 0 | 1 | 2 | |
| Dizziness | 3 | 1 | 1 | 1 | |
| Melena | 2 | 0 | 1 | 1 | |
| Constipation | 2 | 0 | 1 | 1 | |
| Abdominal discomfort2 | 14 | 3 | 7 | 4 |
1
The symptoms of a single adverse event are counted as 1, and a patient may have multiple adverse events.
2
Abdominal discomfort, but not specified.
P values were from two-sided comparisons of the differences among the three treatment groups. 500 mg bid: Tetracycline twice daily; 500 mg tid: Tetracycline three times daily; 750 mg bid: Tetracycline twice daily. N: Number of total patients; n: Number of patients with adverse events.